Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2026Journal of Clinical Oncology

US mortality from coexisting breast cancer and hypertension rises ~5% annually since 1999.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

National mortality trends among individuals with both breast cancer and hypertensive diseases have not been comprehensively characterized.

Population

US adults with coexisting breast cancer and hypertensive diseases from 1999 to 2023

Design

Nationwide retrospective database analysis

Key result

Coexisting breast cancer and hypertensive disease mortality in U.S. adults increased from an AAMR of 1.65 in 1999 to 6.16 in 2023 (AAPC 5.08%; 95% CI 3.32-6.86).

Authors

HMHassan E. MuhammadMSMifrah Rahat Khan SherwaniHAHasan Alajmi

Discussion

Loading...

Member takes

Overview

Rising co-mortality trends warrant integrated cardio-oncology vigilance; extends observational data but leaves causal mechanisms and interventions open.

Key Points

  • This study aims to evaluate long-term mortality trends and disparities among U.S. adults with breast cancer and hypertensive diseases.
  • Evaluated mortality data from CDC WONDER database (1999-2023) using ICD-10 codes for breast cancer and hypertensive diseases.
  • Calculated age-adjusted mortality rates (AAMRs) stratified by demographics and geographic categories.
  • Used Joinpoint regression to analyze temporal trends in mortality rates.
  • AAMRs for those with both conditions increased from 1.65 in 1999 to 6.16 in 2023, with a significant upward trend of 5.08% per year (95% CI: 3.32–6.86).
  • Mortality rose sharply from 2018, with an annual percent change of 22.42% (95% CI: 14.32–31.08).
  • Females had higher mortality rates than males, and significant post-2018 increases were observed across all racial groups.

Study Design

Type

Observational

Multicenter

Yes

Structured PICO

P
Population
U.S. adults with coexisting breast cancer and hypertensive diseases from 1999 to 2023
O
Outcome
Age-adjusted mortality rates (AAMRs) per 100,000 population and temporal trends (annual percent change and average annual percent change)hard clinical

Main Result

Effect estimate: AAPC 5.08% (95% CI 3.32-6.86)

Mortality involving coexisting breast cancer and hypertensive diseases has accelerated significantly in the U.S., particularly after 2018, highlighting growing cardio-oncologic vulnerabilities.

Cite This Study

Muhammad et al. (2026) conducted an observational in Coexisting breast cancer and hypertensive diseases. Coexisting breast cancer and hypertensive disease mortality in U.S. adults increased from an AAMR of 1.65 in 1999 to 6.16 in 2023 (AAPC 5.08%; 95% CI 3.32-6.86).

synapsesocial.com/papers/6a1a81e00307b785094339fchttps://doi.org/10.1200/jco.2026.44.16_suppl.e12716
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Temporal and demographic trends in hypertension-associated breast cancer mortality in the United States: A CDC WONDER analysis (1999–2020).2026
  2. 2Abstract PS4-09-20: Trends and Disparities in Mortality Among U.S. Females with Breast Cancer and Hypertensive Diseases, 1999-20232026
  3. 3Mortality trends and persistent disparities among U.S. adults with lung cancer and hypertensive diseases (1999–2023): A nationwide retrospective analysis.2026
  4. 4Analyzing trends in multimorbidity-related mortality among patients with lung cancer and hypertensive diseases: A 25-year nationwide analysis.2026
  5. 5Cardiovascular mortality trends and disparities in U.S. breast cancer patients, 1999–2020: a population-based retrospective study2024 · 5 citations